Harpoon Therapeutics is a clinical-stage immunotherapy company. Co.'s Tri-specific T cell Activating Construct (TriTACs) product candidates include: HPN328, which is for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217, which is for the treatment of multiple myeloma; and HPN536, which is for the treatment of ovarian and pancreatic cancers and other mesothelin- expressing solid tumors. Co.'s proprietary TriTAC product candidate is HPN601, which targets the epithelial cell adhesion molecule and is being developed for the treatment of multiple solid tumor indications. We show 21 historical shares outstanding datapoints in our HARP shares outstanding history coverage, used to compute HARP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HARP market cap history over the course of time is important for investors
interested in comparing HARP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HARP versus a peer is one thing; comparing
HARP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HARP can fluctuate over the course of history.
With this page we aim to empower investors researching HARP by allowing them to research the HARP market cap history. |
Free HARP Email Alerts:
Video: The Importance of Market Cap
